Autoimmune/Cholestatic/Biliary Diseases News

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.

WASHINGTON — Seladelpar use led to “rapid, marked and sustained improvement” in markers of cholestasis and liver injury among patients with primary biliary cholangitis, according to interim results of the ongoing, phase 3 ASSURE study.

Treatment with Bylvay resulted in a “significantly greater” change from baseline to week 24 in mean scratching scores and serum bile acids vs. placebo among pediatric patients with Alagille syndrome, according to ASSERT study results.

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.

A “significantly greater” percentage of patients with primary biliary cholangitis achieved biochemical response, alkaline phosphatase normalization and reduction in pruritis when treated with seladelpar vs. placebo, according to a study.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.

More than 300 million people worldwide, including one in every 10 Americans, are living with a rare disease, yet these individuals and their families are often left isolated and without answers.

Offspring born to mothers with prenatal or third trimester intestinal infection or genitourinary tract infection experienced a significantly higher risk for biliary atresia, according to a study in JAMA Network Open.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.